This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics' Adcetris Gets EU Nod for Label Expansion
by Zacks Equity Research
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.
J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve
by Zacks Equity Research
J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
Merck Reports Positive Phase III Liver Cancer Data on Keytruda
by Zacks Equity Research
Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib.
Bristol-Myers (BMY) Reports Data from CheckMate-142 Study
by Zacks Equity Research
Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
Foreign Stock Roundup: Taiwan Semiconductor Beats, Shell Buys Stake in Silicon Ranch
by Swarup Gupta
Global markets largely echoed Wall Street's fortunes over last week.
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?
by Arpita Dutt
Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?
by Zacks Equity Research
J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year
by Zacks Equity Research
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
by Zacks Equity Research
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.
Merck Strong on Confirmatory Phase III Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.
Merck (MRK) Jumps: Stock Rises 5.8%
by Zacks Equity Research
Merck (MRK) shares rose nearly 6% in the last trading session, amid huge volumes.
Dow Touches New Intraday High, Finishes Lower
by Benjamin Rains
Merck (MRK), UnitedHealth (UNH), and Coca-Cola (KO) helped lift the Dow Jones Industrial Average above 26,000 on Tuesday, marking the fastest climb between 1,000-point barriers in the index's 121-year history.
With Social Media Use Set to Grow in 2018, Buy Twitter (TWTR)
by Benjamin Rains
The likes of Merck (MRK) and UnitedHealth (UNH) have helped lift the Dow to new heights in 2018, while early gains from Amazon (AMZN) just might have signaled that the tech sector is on track for another outstanding year.
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
by Zacks Equity Research
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
AstraZeneca's Lynparza Label Now Includes Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform
by Zacks Equity Research
Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.
Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
by Zacks Equity Research
Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference
by Arpita Dutt
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.
Merck's Keytruda Combo Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with Eisai's Lenvima gets breakthrough therapy designation from the FDA as a potential treatment for advanced kidney cancer.
Amgen Announces Acceptance of MAA for Evenity in Europe
by Zacks Equity Research
Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.
Merck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study
by Zacks Equity Research
Merck (MRK) announced that a phase III study evaluating Keytruda as monotherapy for the treatment of high-risk melanoma met the primary endpoint.
Cancer Space Update: New Regulatory Status for 3 Major Drugs
by Zacks Equity Research
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Key Biosimilar Approvals in 2017: Progress Report
by Zacks Equity Research
The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.